EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future

Karen Rowland Yeo iD, Eva Gil Berglund, Yuan Chen iD

Clinical Pharmacology & Therapeutics · 2024-09 · 116 (3) · 563-576

DOI: 10.1002/cpt.3289 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 30.04.2024. Verfasst von Karen Rowland Yeo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Certara UK Limited (Simcyp Division), Sheffield, UK. Hauptthemen laut MEDLINE: Models, Biological, Drug Interactions, Drug Development, Pharmacokinetics. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Model‐informed drug development (MIDD) is a powerful quantitative approach that plays an integral role in drug development and regulatory review. While applied throughout the life cycle of the development of new drugs, a key application of MIDD is to inform clinical trial design including dose selection and optimization. To date, physiologically‐based pharmacokinetic (PBPK) modeling, an established component of the MIDD toolkit, has mainly been used for assessment of drug–drug interactions (DDIs) and consequential dose adjustments in regulatory submissions. As a result of recent scientific advances and growing confidence in the utility of the approach, PBPK models are being increasingly applied to provide dose recommendations for subjects with differing ages, genetics, and disease states. In this review, we present our perspective on the current landscape of regulatory acceptance of PBPK applications supported by relevant case studies. We also discuss the recent progress and future challenges associated with expanding the utility of PBPK models into emerging areas for regulatory decision making, especially dose optimization in highly vulnerable and understudied populations and facilitating diversity in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalDrug InteractionsDrug DevelopmentPharmacokineticsHumansDose-Response Relationship, DrugPharmaceutical Preparations

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Certara UK Limited (Simcyp Division), Sheffield, UK.
  • Certara Clinical Drug Development Solutions, Oss, The Netherlands.
  • Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA.

ORCID-Profile: Karen Rowland Yeo, Yuan Chen

Zitieren

APA

Rowland Yeo, K., Gil Berglund, E., & Chen, Y. (2024). Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future. Clinical Pharmacology & Therapeutics, 116(3), 563-576. https://doi.org/10.1002/cpt.3289

Vancouver

Rowland Yeo K, Gil Berglund E, Chen Y. Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future. Clinical Pharmacology & Therapeutics. 2024;116(3):563-576. doi:10.1002/cpt.3289

BibTeX
@article{RowlandYeo2024,
  author = {Rowland Yeo, Karen and Gil Berglund, Eva and Chen, Yuan},
  title = {Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {116},
  number = {3},
  pages = {563--576},
  doi = {10.1002/cpt.3289}
}
Kostenlos starten →